EMP2 and acute lymphoblastic leukemia: Furthermore, based on four datasets of ALL patients (i.e., St Jude, Nat Genet 2013; St Jude, Nat Genet 2015; St Jude, Nat Genet 2016; and TARGET, 2018), the genetic alterations, including amplification and deep deletions, were identified in five genes (i.e., LILRA1, NRGN, VPREN3, EMP2, and FFAR1), with frequencies ranging from 0.4% to 1.8% (Figure 4D).